TITLE

Monitoring high-dose heparin levels by ACT and HMT during extracorporeal circulation: diagnostic accuracy of three compact monitors

AUTHOR(S)
Giavarina, Davide; Carta, Mariarosa; Fabbri, Alessandro; Manfredi, Jacopo; Gasparotto, Edoardo; Soffiati, Giuliano
PUB. DATE
January 2002
SOURCE
Perfusion;Jan2002, Vol. 17 Issue 1, p23
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The correct monitoring of heparin therapy and its reversal determines the successful conduct of cardiovascular surgery with extracorporeal circulation (ECC). The activated coagulation time (ACT) and the heparin management test (HMT) are the most frequently used tests in the operating room. Three compact monitors for ACT or HMT are here evaluated. Forty samples were obtained, at 10-min intervals, from eight patients during ECC. The ACT or HMT was immediately performed using: Hemochron Junior[sup TM] ACT, CoaguCeck[sup TM] Pro (ACT) and Rapid Point Coag (HMT). Data were compared between them and with the heparin levels, measured as anti-Xa. The simple least squares linear regression among, respectively, Hemochron Junior ACT, CoaguCeck Pro ACT, Rapid Point Coag HMT and anti-Xa activity were i = 452.3, s = 15.2, Sy/x = 37.5, r = 0.18; i = 411.9, s = 22.1, Sy/x = 48.7, r = 0.21 and i = 479.4, s = 9.0, Sy/x = 9.3; r = 0.41. CoaguCeck Pro ACT results were above the upper detection limit (500 s) in 37 of 40 determinations. The comparison between ACT Hemocron and HMT Rapid Point Coag shows i = 35.7, s = 0.9, Sy/x = 35.4, r = 0.68, with a bias of 29.0 s (CI: 17.9-40.1), 95% of agreement between -41.5 s (CI: -60.7 to -22.3) and 99.5 s (CI: 80.4-118.7). Taking a concentration of 2.0 U/ml of heparin to discriminate between high- and low-risk conditions, receiver-operator characteristic (ROC) curve was used to rank the performance of the methods. Areas under the ROC curve ± SE for Hemochron Junior ACT and Rapid Point Coag HMT were 0.629 ± 0.097 and 0.543 ± 0.096. The results obtained by HMT appear similar to those obtained by the ACT for monitoring high-dose heparin therapy in patients undergoing ECC. HMT appeared to perform better than ACT in measuring the heparin effect, while the ROC analysis gives a little more accuracy for ACT. Neither of the two methods is able to achieve enough evidence of diagnostic accuracy. Since these tests are widely used, and there are no laboratory alternatives, a real comparison with the outcome of the patients should be helpful for an evidence-based evaluation of these point-of-care tests.
ACCESSION #
6567713

 

Related Articles

  • ECMO: Improving our Results by Chasing the Rabbits. Canêo, Luiz Fernando; Neirotti, Rodolfo A. // Brazilian Journal of Cardiovascular Surgery;Nov/Dec2015, Vol. 30 Issue 6, p657 

    As Marcelo Giugale published in the Financial Times, Latin America, on the whole, has not excelled at innovation - doing the same things in a new and better way or at doing new things. It has been slow to acquire, adopt and adapt technologies by this time available in other places. Although...

  • Hirudin therapy during thrombolysis for venous thrombosis in heparin-induced thrombocytopenia. Reilly, M.P.; Weiss, R.; Askenase, A.; Tuite, C.; Soulen, M.; Mohler III, E.R. // Vascular Medicine;2000, Vol. 5 Issue 4, p239 

    Heparin-induced thrombocytopenia (HIT) is the most common drug-related thrombocytopenia. Thromboembolic complications occur in approximately 50% of patients with HIT and result in limb amputation and death in up to 20% and 30% respectively. Because patients with a history of HIT may require...

  • A weight-based nomogram for heparin dosing.  // Patient Care;1/30/1994, Vol. 28 Issue 2, p100 

    Presents an overview of the scientific paper `The Weight-Based Heparin Dosing Nomogram Compared with a `Standard Care' Nomogram: A Randomized Control Trial,' by R.A. Rasschke, B.M. Reilly, J.R. Guidry and colleagues. Study of patients with venous or arterial thromboembolism or unstable angina;...

  • Contaminated Heparin Associated with Adverse Clinical Events and Activation of the Contact System.  // New England Journal of Medicine;3/18/2010, Vol. 362 Issue 11, p1056 

    A correction to the article "Contaminated Heparin Associated With Adverse Clinical Events and Activation of the Contact System" that was published in the June 5, 2008 issue is presented.

  • Effect of Heparin on the One--Stage Prothrombin Time. Moser, Kenneth M.; Hajjar, George C. // Annals of Internal Medicine;Jun67, Vol. 66 Issue 6, p1207 

    Presents a study that outlined the effects of various doses of intravenous and subcutaneous heparin on the one-stage prothrombin time. Effect of heparin on anticoagulant management of patients receiving heparin concomitantly with prothrombinopenic agents; Description of a patient with...

  • Heparin prophylaxis for medical patients? Lederle, Frank A.; Lederle, F A // Annals of Internal Medicine;05/01/98, Vol. 128 Issue 9, p768 

    Editorial. Provides information on the establishment of heparin prophylaxis for surgical patients. Effectiveness of prophylaxis in hospitalized medical patients; Reference to study conducted; Average cost of prophylaxis per patient.

  • Heparin-associated Thrombocytopenia. King, Derek J.; Kelton, John G. // Annals of Internal Medicine;Apr84, Vol. 100 Issue 4, p535 

    Presents a study which examined the occurrence of thrombocytopenia in patients receiving heparin therapy. Complications of heparin therapy; Details of the clinical characteristics of patients involved in the study; Discussion on the management of patients who receive heparin therapy.

  • Randomised Long-Term Comparison of Tinzaparin and Dalteparin in Haemodialysis. Beijering, R.J.R.; ten Cate, H.; Stevens, P.; Vanholder, R.; van Dorp, W.T.; van Olden, R.W.; Wickström, B.; Sprøgel, P.; ten Cate, J.W. // Clinical Drug Investigation;2003, Vol. 23 Issue 2, p85 

    Objective and design: Tinzaparin and dalteparin are low molecular weight heparins (LMWHs) with different pharmacokinetic and pharmacodynamic profiles that may lead to differences in efficacy and safety. In a long-term, multicentre, prospective, randomised trial we compared the efficacy and...

  • Anticoagulation in heart disease. Hardman, Suzanna M C; Cowie, Martin R; Bettelheim, Eric // BMJ: British Medical Journal (International Edition);01/23/99, Vol. 318 Issue 7178, p238 

    Presents information on a study which discusses the use of warfarin and heparin in patients with heart disease. Methodology; Information on non-rheumatic atrial fibrillation; Factors which increase the risk of thromboembolism; Details on paroxysmal atrial fibrillation.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics